Mouse primary skin fibroblasts were infected with a recombinant retrovirus containing human factor IX cDNA. Bulk infected cells capable of synthesizing and secreting biologically active human factor IX protein were embedded in collagen, and the implant was grafted under the epidermis. Sera from the transplanted mice contain human factor IX protein for at least 10-12 days. Loss of immunoreactive human factor IX protein in the mouse serum is not due to graft rejection. Instead, the mouse serum contains anti-human factor IX antibodies, which react with the protein. We suggest that retroviral-infected primary skin fibroblasts offer an alternative approach to somatic cell gene therapy.
The concept of human gene therapy involves the introduction of a functionally active gene into somatic cells of an affected individual to correct the defect. To ensure lifelong supply of the replaced gene product, it is essential to introduce and express the gene in cells that proliferate during the entire adult life of the recipient. Because pluripotent stem cells in bone marrow have both self-renewal capacity as well as ability to give rise to all hematopoietic lineages, they are a popular target for introducing functionally active genes (1) (2) (3) (4) . Recently, hepatocytes have been used as target cells for introducing functionally active genes (5, 6) .
Murine retroviruses efficiently infect many fibroblast cell lines, including immortalized and normal human diploid fibroblasts (7) (8) (9) (10) and human keratinocytes (11) . This approach to gene transfer offers several advantages: (i) primary skin fibroblasts are readily accessible by skin biopsy and easily cultured and manipulated in vitro; (ii) efficient infection of primary cultures by retroviral vectors reduces the in vitro culturing period; (ifi) use of fibroblasts as target cells for gene transfer overcomes inefficient gene expression by retroviral vectors in other target tissues, such as bone marrow; (iv) because skin fibroblasts reside in a highly vascularized compartment of the dermis, infected cells have direct access to the circulatory system; (v) use of syngeneic primary cultures obviates problems of graft rejection; and (vi) the implanted skin fibroblasts can be conveniently removed. We report the development and characterization of an alternative approach of gene product delivery using mouse skin fibroblasts.
MATERIALS AND METHODS

Construction and Infection by Recombinant Factor IX
Retroviruses. The recombinant pAFFIXSVNeo is based on a retroviral construct pAFVXM generated by Kriegler et al. (12) . A human factor IX cDNA was linked directly to the 5' long terminal repeat (LTR) by inserting a 1.6-kilobase (kb) BamHI/HindIII fragment from the clone CVI between the Bgl II and HindIII sites of pAFVXM (13) . The entire expression unit from the neomycin phosphotransferase expression plasmid (pKoNeo) was excised by partial HindIII digestion and inserted into the HindIII site of the above factor IX viral construct (Fig. la) . "Helper-free" recombinant ecotropic virus in T2 cells was generated as described (14, 15) . The titers ofrecombinant retrovirus expressed from drug-resistant clones were done essentially as described (14) .
Primary mouse embryo fibroblasts (MEF) were obtained from day-17 embryos of C57BL/6J mice (16) . The BL/6 line is an immortalized skin cell line derived from x-ray irradiated skin fibroblasts obtained from C57BL/6J mice. The skin fibroblast cell line BL/6 and NIH 3T3 TK-cells were infected with recombinant retroviruses from the cell line, TFIXNeo 4, at a multiplicity-of-infection (moi) of [1] [2] in the presence of Polybrene at 8 ,ug/ml; MEF cells were infected at a moi of 5. Implantation of Infected Mouse Fibroblasts in Mouse. Infected BL/6 and MEF cells were cultured in an artificial extracellular matrix composed of rat tail type I collagen (1 mg/ml; Sigma) and Dulbecco's modified Eagle's medium (DMEM) supplemented with 10o fetal bovine serum in a 5-cm dish (17, 18) . The cells were cultured at 370C for 3 days during which the collagen lattice contracted to a tissue-like structure (1/25th the area of the original gel). Once contracted, two artificial tissues containing :4 x 106 infected fibroblasts were grafted into the loose connective tissue of the dermis in the mid-back of a recipient C57BL/6 mouse. To ensure rapid vascularization of the grafted tissue, a 2-mm2 piece of Gelfoam (Upjohn) containing 2 ,g of basic fibroblast growth factor was inserted into the loose connective tissue along with each graft. Serum samples were drawn at 2-day intervals and analyzed for the presence of human factor IX by ELISA.
Analysis of Secreted Factor IX. Levels of antigenic factor IX were assayed by ELISA as described by Anson et al. (19) . Biologically active human factor IX was immunoaffinity-purified using A7 antibody (19, 20) . The amount of biologically active protein was determined by a one-step clotting assay using canine factor IX-deficient plasma (21) . This assay is based on the ability of the sample to decrease the prolonged activated partial thromboplastin time of congenital factor IX-deficient plasma. Purified human factor IX was used as a control. IX into the culture media, albeit at different levels (see Fig.  2 ).
RESULTS
Transduction of Neomycin
We determined the organization of the integrated recombinant retrovirus in the virus-producing cell line by Southern blot analysis of Sst I-digested (Sst I cleaves once in each LTR to generate a 5.1-kb DNA fragment (Fig. lb) genomic DNA. All infected cells displayed a single band of the expected size of -5.1 kb, which hybridizes to both the factor IX cDNA and the Neo probe, therefore ruling out any detectable rearrangements. Furthermore, the size of this band in infected NIH 3T3 TK-, BL/6, and MEF cells is identical to that found in the virus-producing cell line TFIXNeo 4 (compare lanes 5 and 9 to other lanes). (19) . The mouse anti-human monoclonal antibody, FXCO08, generated by Bajaj et al. (22) was used as the primary antibody, whereas pooled normal human sera were used as a standard. Each time point was done in triplicate and thus represents an average amount of factor IX secreted over a 48-hr period.
Curves were corrected for the slight increase in cell number over this period.
The RNA blot analysis of the RNA isolated from TFIXNeo 4, infected NIH 3T3 TK -, BL/6, and MEF is shown in Fig. lc . When hybridized to factor IX probe, only one major transcript of the expected size of 5.1 kb, corresponding to full-length viral RNA, could be detected in the infected cells. Hybridization with Neo probe reveals an additional 2.2-kb transcript that is the predicted size of the mRNA species, the synthesis of which is initiated from the simian virus 40 early promoter and is terminated in the 3' LTR (Fig. lc) . Ratios of the steady-state levels of the 5.1-kb and the 2.2-kb transcripts varied within the different infected cell types. From results shown in Fig. 1 , we conclude that the TFIXNeo recombinant retrovirus is properly integrated and expressed in the infected cells.
Secretion of Factor IX Protein. Because human factor IX is a secretory protein we wanted to verify whether it is secreted into the medium of the infected cells. Fig. 2 shows that both rate and extent of antigenic factor IX released into the medium is dependent on cell type rather than on relative amounts of the factor IX transcripts. For instance, steadystate levels of factor IX transcript in infected NIH 3T3 TKcells is much higher than in BL/6 cells (Fig. lc) ; yet, the rate and amount offactor IX secreted in the latter cell type is much higher. Both the virus-producing cell line TFIXNeo 4 and infected skin fibroblast cell line BL/6 secreted antigenic factor IX at similar rates--5.7 ng per ml/hr for 3 x 106 cells and 5.0 ng per ml/hr for 3 x 106 cells, respectively. This rate was almost 3-fold higher than the rate of factor IX secretion seen for infected MEF (1.75 ng per ml/hr for 3 x 106 cells) and infected NIH 3T3 cells (1.65 ng per ml/hr for 3 x 106 cells). These results indicate that the rate of synthesis and/or secretion may be a property of the cell type, rather than the levels of expression.
Secreted Human Factor IX Protein Is Biologically Active. The primary translation product of factor IX gene undergoes extensive post-translational modification, which include addition of sialic carbohydrates (23, 24) , vitamin K-dependent conversion of glutamic acid residues to 'y-carboxy/glutamic (25) and f8-hydroxylation of aspartic acid residue 64 (26) . The y-carboxylation of factor IX is essential for clotting activity, and this modification generally occurs in the liver, the primary source of factor IX synthesis in the body. We took two different approaches to assess biological activity of human factor IX secreted from cells in culture: (i) the infected mouse embryo fibroblasts were cultured in factor IX-deficient canine serum obtained from hemophiliac dogs, supplemented with epidermal growth factor (10 ng/ml) and vitamin K (25 ng/ml). Media harvested after 48-hr incubation was monitored for activity by a one-step assay (21) . Conditioned media from MEF cells contained biologically active human factor IX at 210 ng/ml, which is similar to the levels seen with ELISA assays (Fig. 4) (Fig. 3A) . Fig. 3B shows that the inserted implants were extensively vascularized by day 14 . A similar extent of vascularization was also detected in 28-day implants (data not shown).
The serum levels of the human clotting factor were measured in engrafted mice by ELISA over a 34-day period. Fig.   4 shows that the average levels of human factor IX in three mice progressively increased from 20 ng/ml at day 2 to a peak of 97 ng/ml 7 days after grafting the BL/6 cells into the mice. The four mice grafted with the infected MEF fibroblasts showed a similar pattern of increase, in which an average peak of 25 ng/ml of factor IX was detected at day 9. This rise was followed by a rapid decline to near nondetectable levels of serum human factor IX at day 16 Detection of mouse anti-human factor IX antibodies in mice grafted with collagen implants. Purified human factor IX was subjected to PAGE under denaturing conditions and then transferred onto nitrocellulose as described (27) . The nitrocellulose strips were treated with blocking solution for 2 hr followed by 1 5 ). The levels of anti-human factor IX IgG antibodies were not detectable in mice with MEF grafts at day 7 to day 21. Slightly higher levels of serum antibodies were detected in mice with BL/6 grafts during this period-presumably because they are releasing more factor IX. Maximum levels of anti-human factor IX antibodies were detected at day 28 in mice with either graft. The mice with BL/6 grafts exhibited the highest level of xenoantibodies. Pooled serum drawn from mice 28 days after i.p. injection with infected MEF also showed anti-factor IX IgG antibodies, albeit at much lower levels. Naive animals, which have not been exposed to infected BL/6 or MEF cells, do not make anti-human factor IX antibodies. These observations would suggest that human factor IX is continuously produced in grafted mice but is not detectable due to a large pool of mouse anti-human factor IX antibodies.
DISCUSSION
We present the development and characterization of a different approach of gene product delivery into an animal model system. The BL/6 cells and MEF cells infected with a helper-free recombinant retroviral vector containing the human clotting factor IX cDNA secrete partially biologically active clotting factor at a rate 10-fold higher than seen with another retroviral vector containing the human clotting factor cDNA (19) . In addition, we have demonstrated that these genetically modified cells can be reintroduced into the loose connective tissue of the dermis of a syngeneic mouse.
Grafts are quickly vascularized in the presence of angiogenic factor, fibroblast growth factor, and remain vascularized for at least 28 days. Grafts containing the BL/6 cells grow as aggressive tumors over this period, while the size of the grafts containing MEF cells does not increase over the same period. The clotting factor secreted from the infected cells in the graft is accessible to the circulatory compartment and can easily be detected in serum of the recipient. Functional status of the infected cells in the grafts can be measured by monitoring serum levels of human factor IX or by the ability of explanted cells to continue secreting the human protein.
However, C57BL/6 mice recognize the human blood clotting factor as foreign and thus mount a strong humoral immune response against it. Although a humoral response against factor IX clearly exists, there does not appear to be a major cell-mediated response against the cells in the grafts. The cells in the graft are still viable after 28 days of implantation and continue to synthesize factor IX protein.
Recently two groups have used mouse fibroblasts to introduce and express foreign genes in mice (28, 29) . One group implanted mice with DNA-transfected cell line and showed that the recipient mice made the gene product (growth hormone) and maintained the graft only if the mice are immunosuppressed (28) . The other group using retroviral vectors containing a1-antitrypsin gene generated a cell line 3154 Medical Sciences: St. Louis and Verma and then transplanted them into the peritoneal cavity of nude mice (29) . In both cases cell lines were generated that would potentially be tumorigenic in mice. Neither study addresses the issue of cell maintenance in grafted mice without the use of harsh immunosuppressive agents. Moreover, because of their potential tumorigenicity it is not advisable to generate syngenic human diploid cell lines and use them for introducing foreign genes. The method we have described obviates the need for cell lines and instead essentially uses the cells of recipient mice, minimizing the possibility of rejection. Culturing the cells in collagen matrix circumvents the problem of necrosis that would ensue following s.c. injection (30 (Fig.  4) . In larger animals multiple grafts of up to 108 cells can be easily implanted, increasing the levels of factor IX protein to that required to alleviate the deficiency. (ii) Improved culturing conditions-culturing infected cells in a defined medium (without fetal bovine serum) and improved technology for reconstitution of living skin would also increase the efficiency of the system (30) . Moreover, improved surgical skills may ensure that the implant would lay flat in the dermal compartment of the mouse skin to allow more uniform vascular development and hence improve cell viability during the brief period required for vascularization. Although the extent of cell viability has not yet been determined in grafts containing MEF cells, experiments in rats have shown that transplanted fibroblasts persist for at least 13 months (30).
In conclusion, we have shown that skin fibroblasts can be used as a viable mode of introduction and expression of foreign genes in animals. The process of manipulation of genetically engineered fibroblasts appears to be both less complex and cumbersome than the widely accepted use of bone marrow transplantation for somatic cell gene therapy.
